Estrogen receptor ligands. Part 10: Chromanes: old scaffolds for new SERAMs.

Article Details

Citation

Tan Q, Blizzard TA, Morgan JD 2nd, Birzin ET, Chan W, Yang YT, Pai LY, Hayes EC, DaSilva CA, Warrier S, Yudkovitz J, Wilkinson HA, Sharma N, Fitzgerald PM, Li S, Colwell L, Fisher JE, Adamski S, Reszka AA, Kimmel D, DiNinno F, Rohrer SP, Freedman LP, Schaeffer JM, Hammond ML

Estrogen receptor ligands. Part 10: Chromanes: old scaffolds for new SERAMs.

Bioorg Med Chem Lett. 2005 Mar 15;15(6):1675-81.

PubMed ID
15745820 [ View in PubMed
]
Abstract

The discovery, synthesis, and SAR of chromanes as ER alpha subtype selective ligands are described. X-ray studies revealed that the origin of the ER alpha-selectivity resulted from a C-4 trans methyl substitution to the cis-2,3-diphenyl-chromane platform. Selected compounds from this class demonstrated very potent in vivo antagonism of estradiol in an immature rat uterine weight assay, effectively inhibited ovariectomy-induced bone resorption in a 42 days treatment paradigm, and lowered serum cholesterol levels in ovx'd adult rat models. The best antagonists 8F and 12F also exhibited potent inhibition of MCF-7 cell growth and were shown to be estrogen receptor down-regulators (SERDs).

DrugBank Data that Cites this Article

Binding Properties
DrugTargetPropertyMeasurementpHTemperature (°C)
(2R,3R,4S)-3-(4-HYDROXYPHENYL)-4-METHYL-2-[4-(2-PYRROLIDIN-1-YLETHOXY)PHENYL]CHROMAN-6-OLEstrogen receptor alphaIC 50 (nM)1.5N/AN/ADetails
Compound 4-DEstrogen receptor alphaIC 50 (nM)0.8N/AN/ADetails
EstradiolEstrogen receptor alphaIC 50 (nM)1.3N/AN/ADetails
EstradiolEstrogen receptor betaIC 50 (nM)1.1N/AN/ADetails